Allergy Therapeutics (AGY)

 

AGY Share PerformanceMore

52 week high28.50 17/10/16
52 week low17.25 26/09/16
52 week change -0.87 (-3.25%)
4 week volume4,898,882 01/02/17

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Broker Forecast - Stifel issues a broker note on Allergy Therapeutics PLC

Stifel today reaffirms its buy investment rating on Allergy Therapeutics PLC (LON:AGY) and set its price target at 60p.

Allergy Therapeutics vaccine gains CTA spproval

Allergy Therapeutics has received approval for a clinical study of its novel house dust mite allergy vaccine. The company s...

House Dust Mite Allergy Vaccine Gains CTA Approval

RNS Number: 7777W Allergy Therapeutics PLC 14 February 2017 Al l e r g y Th e r a p e u ti cs p l c (" A l l e r gy T he r a peu t i cs" or t he " C o m p a n y " ) Novel House Dust Mite Allergy Vaccine Gains Clinical Trial Application Approval CTA approval in Spain for Phase I AM101 clinical study evaluating safety of adjuvanted, modified house dust mite allergy v...

Directorate Change

RNS Number: 2838W Allergy Therapeutics PLC 08 February 2017 8 February 2 0 17 A l l e r g y Th e r a p e u ti cs p l c (" A l l e r gy T he r a peu t i cs" or t he ' C o m p a n y " ) Directorate Change Allergy Therapeutics (AIM:AGY), the fully integrated specialty pharmaceutical company specialising in allergy vaccines, announces the appointment of Mr Jeff Barton t...

Allergy Therapeutics positive data in peanut allergy vaccine

Allergy Therapeutics has announced positive results from preclinical research into its unique therapeutic peanut allergy va...

Positive Efficacy & Safety Data in Peanut Vaccine

RNS Number: 6674V Allergy Therapeutics PLC 01 February 2017 Al l e r g y Th e r a p e u ti cs p l c (" A l l e r gy T he r a peu t i cs" or t he " C o m p a n y " ) Positive Efficacy and Safety Data Shown in Peanut Allergy Vaccine 1 February 2017 Allergy Therapeutics (AIM:AGY) , the fully integrated specialty pharmaceutical company specialising in allergy vaccines , ...

Hardman Research: Investment driving market share

RNS Number: 6686U Allergy Therapeutics PLC 20 January 2017 Hardman Research: Investment driving market share gains Investment driving market share gains: AGY is a long-established specialist in the prevention, diagnosis and treatment of allergies. Pollinex Quattro continues to gain market share despite being available in Europe only on a 'Named Patient' basis...

Broker Forecast - finnCap issues a broker note on Allergy Therapeutics PLC

finnCap today reaffirms its buy investment rating on Allergy Therapeutics PLC (LON:AGY) and raised its price target to ...

Fundamental DataMore

EPS-2.29
Dividend yield0 %

Equity Research (AGY)

Allergy Therapeutics plc
15/11/2016
InnovaDerma* (IDP.L) 107.5p £10.98m Strong news flow this week from the main market listed  UK developer of 'at-home' and clinically proven treatments for hair loss, hair care, self-...
hardman & co
Allergy Therapeutics plc
26/09/2016
AGY is a long-established specialist in the prevention, diagnosis and treatment of allergies. Pollinex Quattro continues to gain market share despite being available in Europe only on a ‘Named...
hardman & co
Allergy Therapeutics plc
07/06/2016
AGY is a long-established specialist in the prevention, diagnosis and treatment of allergies. It’s lead product, Pollinex Quattro is available in Europe only on a ‘Named Patient’ basis. However,...

Latest discussion posts More

  • Interviews

    This is taken from another ...
    15-Feb-2017
    Baffler
  • Re: Stifel reaffirm BUY rec - target 60p

    Haven't they dropped the target from 79p about a year ago? Mind you I'm not greedy and I like/hope for this company. CL
    15-Feb-2017
    Chicken Lips
  • Stifel reaffirm BUY rec - target 60p

    Now Stifel up the anti to 60p Broker Forecast - Stifel issues a broker note on Allergy Therapeutics PLC Tue, 14th February 2017 - 11:20 Stifel today reaffirms its ...
    15-Feb-2017
    Baffler

Users' HoldingsMore

Users who hold Allergy Therapeutics also hold..
LLOYDS GRP.27%
BP18%
BARCLAYS17%
NATIONAL GRID14%
GLAXOSMITHKLINE14%

Codes & Symbols

ISINGB00B02LCQ05
SymbolsAGY, LSE:AGY, AGY.L, AGY:LN, LON:AGY, XLON:AGY